Incyte | INCY - Spese Di Vendita E Di Amministrazione





Spese Di Vendita E Di Amministrazione Cambiamento Data
Acadia Pharmaceuticals USD 148.57M 12.22M 2026-06
Agenus USD 6.21M 4.34M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 347.92M 65.41M 2026-06
Amgen USD 1.72B 134M 2026-06
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Biogen USD 709.7M 155.4M 2026-06
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Eli Lilly USD 3.43B 496M 2026-06
Exelixis USD 147.63M 8.03M 2026-06
Gilead Sciences USD 1.52B 70M 2026-06
Incyte USD 351.73M 23.64M 2026-06
Ionis Pharmaceuticals USD 130.07M 20.92M 2026-06
MacroGenics USD 9.71M 1.77M 2026-03
Merck USD 2.89B 219M 2026-06
Moderna USD 216M 43M 2026-06
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.24B 101M 2026-06
Novartis USD 3.14B 296M 2026-03
Pfizer USD 3.41B 496M 2026-06
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Sarepta Therapeutics USD 107.6M 53.57M 2026-06
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06